apl. Prof. Dr. Markus Heppt

Medizinische Fakultät Department of Dermatology

Inter-Rater Agreement in Assessing Risk of Bias in Melanoma Prediction Studies Using the Prediction Model Risk of Bias Assessment Tool (PROBAST): Results from a Controlled Experiment on the Effect of Specific Rater Training (2023) Kaiser I, Pfahlberg AB, Mathes S, Uter W, Diehl K, Steeb T, Heppt M, Gefeller O Journal article Conventional and three-dimensional photography as a tool to map distribution patterns of in-transit melanoma metastases on the lower extremity (2023) Müller K, Berking C, Voskens C, Heppt M, Heinzerling L, Koch E, Kramer R, et al. Journal article Identifying biomarkers and novel therapeutic targets in uveal melanoma (2023) Wessely A, Koch E, Vera J, Berking C, Heppt M Journal article Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. (2023) Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, Garzarolli M, et al. Journal article Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial (2023) Koch E, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, Gutzmer R, et al. Journal article Cutaneous squamous cell carcinoma: state of the art, perspectives and unmet needs (2023) Heppt M, Leiter U Journal article Wissen über nicht-melanozytären Hautkrebs in der Allgemeinbevölkerung: eine multi-methodische Studie (2023) Brokmeier L, Görig T, Spaehn BA, Heppt M, Breitbart EW, Diehl K Conference contribution, Abstract of a poster One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website-A Mixed-methods Approach (2022) Steeb T, Bruetting J, Reinhardt L, Hoffmann J, Weiler N, Heppt M, Erdmann M, et al. Journal article eImmunonkologie: Development and Launch of a Virtual Education Platform for the Immunotherapy of Cutaneous Neoplasms (2022) Kaufmann M, Steeb T, Wessely A, Meyerolbersleben M, French LEE, Berking C, Heppt M Journal article Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland (2022) Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akcetin L, et al. Journal article